Review Article
Hepatitis C Infection: A Clinical Review
Abstract
Nearly three million persons in the United States are viremic with hepatitis C (HCV). Despite a decreasing incidence of HCV in this country, the prevalence of HCV-related chronic liver disease is increasing. Most infections in the United States are acquired by intravenous drug use. The chronicity rate of HCV is high, reaching 85% in some populations, and the risk of progression to advanced liver disease is as high as 20% within twenty years of infection. Host factors like alcohol use accelerate the rate of progression. The enzyme immunoassay is the preferred initial test for diagnosis; the third generation assay has greater than a 99% specificity in immunocompetent patients. Barring contraindications, the standard of care for treatment of chronic HCV has become pegylated interferon and ribavirin. With this therapy, the cure rate for treatment-naïve patients is about 55%, but rates are higher in certain groups. Common side effects of therapy include neuropsychiatric symptoms, influenza-like symptoms and hematological abnormalities.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Choo QL, Weiner AJ, Overby LR, et al. Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 1989; 244: 359–62.
2. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570–83.
3. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394–15399.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999; 341: 556–562.
5. National Commission on Correctional Health Care, National Institute of Justice (2002). The health status of soon-to-be released inmates. Washington DC: United States Department of Justice.
6. Alter MJ, Margolis HS. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998; 47( RR-19): 1.
7. Kim WR. The burden of hepatitis C in the US. Hepatology 2002; 36: S30–S34.
8. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant 2003; 9: 331–338.
9. Garfein RS, Vlahou D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655–661.
10. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691–1696.
11. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93–S98.
12. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262: 1201–1205.
13. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophiliac males. Blood 1992; 80: 540–543.
14. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995; 345: 1209–1211.
15. Zylberberg H, Thiers V, Lagorce D, et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 1999; 45: 112–116.
16. Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001; 96: 3138–3141.
17. Chayama K, Kobayashi M, Tsubota A, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol 1995; 22: 431–439.
18. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted disease clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 768–775.
19. Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993; 12: 827–831.
20. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 170: 103–106.
21. Healy CM, Cafferkey MT, Conroy A, et al. Outcome of infants born to hepatitis C infected women. Ir J Med Sci 2001; 170: 103–106.
22. Matubara T, Sumazaki R, Takita H. Mother-to-infant transmission of hepatitis C virus: a prospective study. Eur J Pediatr 1995; 154: 973–978.
23. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744–750.
24. Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995; 84: 251–255.
25. Paccagnini S, Prinicipi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995; 14: 195–199.
26. Zanetti AR, Tanzi E, Romano L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41: 208–212.
27. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317: 437–441.
28. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 34: 223–229.
29. Delamare C, Carbonne B, Heim N, et al. Detection of hepatitis C virus RNA in amniotic fluid: a prospective study. J Hepatol 1999; 31: 416–420.
30. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98–104.
31. Hoofnagle JH. The course and outcome of hepatitis C. Hepatology 2002; 36: S21–S29.
32. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183–1191.
33. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639–644.
34. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1949–1950.
35. Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631–634.
36. Mutimer D, Shaw J, Neuberger J, et al. Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A, non-B hepatitis. Gut 1995; 36: 433–436.
37. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–1233.
38. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866–870.
39. Shakil AO, Conry-Canilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330–337.
40. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 2119–2124.
41. Alric L, Fort M, Izopet J, et al. Genes of the major histocompatability complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675–1681.
42. Gerlach JT, Diepolder HM, Zachoral R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80–88.
43. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450–456.
44. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933–941.
45. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339–344.
46. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C infection. Medicine 2000; 79: 47–56.
47. El-Serag H, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439–1445.
48. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients in hepatitis C virus infection. Ann Intern Med 1998; 129: 294–298.
49. Hilsabeck R, Perry W, Hassanein T. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440–446.
50. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38–39.
51. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion- associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
52. DiBisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969–974.
53. Benvegnu L, Pontisso P, Cavalleto D, et al. Lack of correlation between hepatitis C genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25: 211–215.
54. Wong JB, Poynard T. The natural history of fibrosis in chronic hepatitis C. Hepatology. 2003; 38( Supl. 1): 182A.
55. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.
56. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5.
57. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of the Hepatitis C Virus. Hepatology 1997; 26: 485–490.
58. Gad A, Tanaka E, Orii K, et al. Relationship between hepatitis C virus infection and schistosomal liver disease: not simply an additive effect. J Gastroenterol 2001; 36: 753–758.
59. Casaril M, Stanzial AM, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000; 47: 220–225.
60. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408–2414.
61. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358–1364.
62. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717–1722.
63. Zhang T, Li Y, Lai JP, et al. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003; 38: 57–65.
64. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311–1316.
65. Kew MC, Mimi Cy, Kedda M, et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112: 184–187.
66. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179–183.
67. Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002; 95: 331–339.
68. Yamauchi M, Nakahara M, Maezawa Y, et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993; 88: 39–43.
69. United Network for Organ Sharing. Organ Procurement and Transplant Network (OPTN) data as of March 1, 2002. Transplants by diagnosis: January 1991 to November 2001. Available athttp://www.unos.org. Accessed on January 10, 2003.
70. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–S46.
71. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74–S83.
72. McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer. Am J Gastroenterol 1996; 91: 1516–1522.
73. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferase to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1250–1257.
74. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413–417.
75. Inglesby TV, Rai R, Astemborski J, et al. A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29: 590–596.
76. Pouti C, Magrini A, Statl T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393–1398.
77. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 1225–1275.
78. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double-blind, placebo controlled trial. N Engl J Med 1989; 321: 1506–1510.
79. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506.
80. Alter HJ. New kid on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology. 1992: 350–351.
81. Pawlotsky JM. Use and interpretation of virologic tests for hepatitis C. Hepatology 2002; 36: S65–S73.
82. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131–1136.
83. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody test to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 1993; 168: 1343–1348.
84. Pawlotsky JM. Critical issues in HCV: HCV diagnostics. 2004. Available athttp://www.hivandhepatitis.com/essays/121503hcv.html. Accessed January 1, 2004.
85. Lee Sc, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38: 4171–4179.
86. Ross RS, Viazov SO, Hoffmann S, et al. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitatitve detection of hepatitis C RNA. J Clin Lab Anal 2001; 15: 308–313.
87. Shiffman ML, Ferreira-Gonzalez A, Reddy KR, et al. Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003; 98: 1159–1166.
88. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 1485–1492.
89. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Interventional Therapy Group. Lancet 1998; 352: 1426–1432.
90. Bouier-Alias M, Patel K, Dahari H, et al. Clinical utility of total hepatitis C virus core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002; 36: 211–218.
91. Lunel F, Veillon P, Payan C. Evaluation of the ortho total HCV core antigen assay in comparison to methods of detection and quantification for HCV RNA. AASLD, Boston Ma, 2002; 759A.
92. Sheth S, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol 1998; 93: 44–48.
93. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999; 44: 1249–1253.
94. Gianni E, Risso D, Botta F, et al. Validity and clinical utility of the AST/ALT ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Int Med 2003; 163: 218–224.
95. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = l is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43: 2156–2159.
96. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95: 2328–2332.
97. McHutchison JG, Blatt LM, deMedina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000; 15: 945–951.
98. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of pegylated interferon alfa-2b and ribavirin. Hepatology 2003; 38: 481–492.
99. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–1340.
100. Serfaty L, Poujol-Robert A, Carbonell N, et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97: 1807–1812.
101. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357–360.
102. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36( supl 1): S84–92.
103. Caturelli E, Bartolucci F, Biasini E, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397–405.
104. Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. J Hepatol 2001; 34: 570–575.
105. Lau DT, Kleiner DE, Ghany MG, et al. Ten year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–1127.
106. Linday KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114–S120.
107. Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001; 3: 30–37.
108. Lau JY, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996; 124: 868–876.
109. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
110. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
111. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904–909.
112. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34: 268–271.
113. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288–292.
114. Yawn BP, Wollan P, Gazzuola L, et al. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002; 51: 135–140.
115. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–966.
116. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1091–1099.
117. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin and interferon alfa. Am J Gastroenterol 2003; 98: 2491–2499.
118. Afdhal NH, Goon B, Smith K, et al. Epoetin-alfa improves and maintains helath-related quality of life in anemic HCV-infected patients receiving interferon/ribavirin: HRQL from the Proactive Study. Hepatology. 2003; 38( supl 1): 302–303A.
119. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Available at http://consensus.nih.gov. Accessed June 23, 2003.
120. Watters JK, Estilo MJ, Clark GL, et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 12: 115–120.
121. Blumenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange on high-risk injection drug users: a cohort study. AIDS 2000; 14: 605–611.
122. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among infection drug users in the Tacoma Syringe Exchange Program. Am J Public Health 1995; 85: 1531–1537.
123. Hagan H, McGough JP, Thiede H, et aL. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203–213.
124. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998; 47: 1–33.
125. Terrault NA. Sexual activity as a risk factor for hepatitis C infection. Hepatology 2002; 36: S99–S105.
126. Cody SH, Nainan OV, Garfein RS, et al. Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med 2002; 162: 345–350.
127. Ross RS, Viazou S, Gross T, et al. Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients. N Engl J Med 2000; 343: 1851–1854.
128. Esteban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555–560.
129. Duckworth GJ, Heptonstall J, Aitken C. Transmission of hepatitis C virus from a surgeon to a patient. Commun Dis Public Health 1999; 2: 188–192.
130. Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch Intern Med 2000; 160: 2313–2316.
131. Associated Press. Hepatitis-infected surgeon must get consent. State directive says consent necessary before operating. Available at http://www.wnbc.com. Accessed April 19, 2002.
132. Everhart JE, DiBisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112: 544–545.
133. Hou CH, Chen WY, Kao JH, et al. Intrafamilial transmission of hepatitis C virus in hemodialysis patients. J Med Virol 1995; 45: 381–385.
134. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286–290.
135. Papaeuangelou G, Lassopoulous N, Roumeliotou-Karayannis A, et al. Etiology of fulminant viral hepatitis in Greece. Hepatology 1984; 4: 369–372.
136. Lee WM. Acute liver failure. N Engl J Med 1993; 329: 1862–1872.
137. Arguedas MR, Heudebert GR, Fallon MB, et al. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002; 97: 721–728.
138. Jacobs RJ, Koss RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: 427–434.
